Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
1.01
Dollar change
+0.01
Percentage change
1.00
%
IndexRUT P/E- EPS (ttm)-0.84 Insider Own3.38% Shs Outstand184.46M Perf Week-0.98%
Market Cap188.16M Forward P/E- EPS next Y-0.74 Insider Trans-1.23% Shs Float178.22M Perf Month-21.09%
Income-168.30M PEG- EPS next Q-0.13 Inst Own74.38% Short Float2.49% Perf Quarter-20.47%
Sales93.14M P/S2.02 EPS this Y51.45% Inst Trans3.98% Short Ratio2.63 Perf Half Y-13.68%
Book/sh0.27 P/B3.81 EPS next Y-5.38% ROA-44.87% Short Interest4.44M Perf Year102.45%
Cash/sh1.31 P/C0.77 EPS next 5Y-7.30% ROE-161.63% 52W Range0.46 - 1.93 Perf YTD78.76%
Dividend Est.- P/FCF- EPS past 5Y- ROI-72.09% 52W High-47.61% Beta0.57
Dividend TTM- Quick Ratio4.24 Sales past 5Y-20.42% Gross Margin67.80% 52W Low121.98% ATR (14)0.07
Dividend Ex-Date- Current Ratio4.24 EPS Y/Y TTM46.09% Oper. Margin-145.91% RSI (14)37.99 Volatility5.03% 6.92%
Employees137 Debt/Eq4.22 Sales Y/Y TTM5.53% Profit Margin-180.70% Recom2.50 Target Price4.16
Option/ShortYes / Yes LT Debt/Eq3.78 EPS Q/Q26.42% Payout- Rel Volume1.22 Prev Close1.00
Sales Surprise25.81% EPS Surprise9.55% Sales Q/Q-0.08% EarningsNov 07 AMC Avg Volume1.69M Price1.01
SMA20-3.76% SMA50-17.10% SMA200-19.95% Trades Volume2,058,410 Change1.00%
Date Action Analyst Rating Change Price Target Change
Dec-10-24Initiated H.C. Wainwright Buy $6.50
Nov-04-24Initiated Piper Sandler Overweight $7
Sep-30-24Resumed BTIG Research Buy $4
Jun-28-24Initiated Rodman & Renshaw Buy $2
Nov-20-23Resumed JP Morgan Underweight
Nov-09-23Upgrade TD Cowen Market Perform → Outperform
May-10-23Upgrade Jefferies Underperform → Hold $1.50 → $1
Feb-24-23Downgrade Jefferies Hold → Underperform $3.20 → $1.50
Aug-08-22Downgrade JP Morgan Neutral → Underweight
May-31-22Resumed Jefferies Hold $12 → $4
Dec-07-24 12:00PM
Nov-18-24 03:30PM
Nov-08-24 02:30AM
Nov-07-24 05:40PM
04:36PM
04:15PM Loading…
04:15PM
10:15AM
Nov-06-24 06:00PM
Nov-05-24 10:34AM
Nov-04-24 01:44PM
08:30AM
Oct-31-24 06:00PM
Oct-29-24 09:00AM
Oct-17-24 12:07PM
Sep-25-24 03:30AM
09:00AM Loading…
Sep-03-24 09:00AM
Aug-13-24 12:00PM
Aug-09-24 10:58AM
Aug-08-24 05:55PM
04:49PM
04:15PM
Aug-01-24 06:00PM
Jun-12-24 09:30AM
May-30-24 06:00PM
May-10-24 04:41PM
03:14PM
11:33AM
10:35AM
May-09-24 05:39PM
04:15PM
06:00PM Loading…
May-02-24 06:00PM
Apr-03-24 11:30AM
Mar-25-24 10:00AM
Mar-22-24 02:00PM
Mar-06-24 12:33PM
Mar-05-24 10:07AM
09:13AM
09:00AM
07:19AM
Mar-04-24 05:30PM
04:51PM
04:42PM
04:15PM
08:30AM
Feb-27-24 06:00PM
Feb-26-24 06:00PM
Feb-20-24 10:00AM
Jan-03-24 06:00PM
Dec-11-23 06:00PM
Dec-07-23 11:31AM
Nov-09-23 08:39AM
Nov-08-23 11:47AM
Nov-07-23 05:28PM
04:15PM
Oct-31-23 06:00PM
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Oct-13-23 08:30AM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
Sep-14-23 07:54AM
Sep-13-23 09:00AM
Sep-07-23 11:31AM
Sep-06-23 06:00PM
Aug-17-23 07:02PM
Aug-09-23 09:25AM
Aug-08-23 05:30PM
04:23PM
04:15PM
11:08AM
Aug-07-23 10:23AM
06:30AM
Aug-01-23 06:00PM
Jul-24-23 03:48AM
Jul-16-23 08:49AM
Jun-12-23 06:00PM
Jun-08-23 12:55PM
11:31AM
May-10-23 11:28AM
09:16AM
May-09-23 06:45PM
05:41PM
04:15PM
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zalevsky JonathanChief R&D OfficerNov 19 '24Sale1.017,7857,863243,019Nov 20 08:37 PM
Wilson Mark AndrewChief Legal OfficerNov 19 '24Sale1.016,4076,471218,856Nov 20 08:36 PM
ROBIN HOWARD WPresident & CEONov 19 '24Sale1.0116,27816,441832,080Nov 20 08:36 PM
Zalevsky JonathanOfficerNov 19 '24Proposed Sale1.017,7857,878Nov 19 04:10 PM
Wilson Mark AndrewOfficerNov 19 '24Proposed Sale1.016,4076,483Nov 19 03:28 PM
ROBIN HOWARD WOfficerNov 19 '24Proposed Sale1.0116,27816,472Nov 19 03:17 PM
Zalevsky JonathanChief R&D OfficerAug 19 '24Sale1.286,8668,788250,804Aug 20 09:15 PM
Wilson Mark AndrewChief Legal OfficerAug 19 '24Sale1.285,6517,233225,263Aug 20 09:15 PM
ROBIN HOWARD WPresident & CEOAug 19 '24Sale1.2814,88119,048848,358Aug 20 09:14 PM
Wilson Mark AndrewOfficerAug 19 '24Proposed Sale1.285,6517,211Aug 19 04:13 PM
ROBIN HOWARD WOfficerAug 19 '24Proposed Sale1.2814,88118,990Aug 19 04:03 PM
Zalevsky JonathanOfficerAug 19 '24Proposed Sale1.286,8668,762Aug 19 03:45 PM
CHESS ROBERTDirectorJun 14 '24Sale1.2019,50023,400255,273Jun 14 06:02 PM
ROBIN HOWARD WPresident & CEOMay 17 '24Sale1.7516,65029,138863,239May 20 09:14 PM
Zalevsky JonathanChief R&D OfficerMay 17 '24Sale1.757,35512,871257,670May 20 09:13 PM
Wilson Mark AndrewChief Legal OfficerMay 17 '24Sale1.756,26010,955230,414May 20 09:12 PM
Deep Track Capital, LP10% OwnerMay 10 '24Sale1.7856,00099,63018,344,000May 13 04:36 PM
Zalevsky JonathanChief R&D OfficerFeb 20 '24Sale0.689,0146,130265,025Feb 22 08:19 PM
Wilson Mark AndrewChief Legal OfficerFeb 20 '24Sale0.687,6065,172236,674Feb 22 08:17 PM
ROBIN HOWARD WPresident & CEOFeb 20 '24Sale0.6820,03313,622879,889Feb 22 08:16 PM